Starting a new standard of care using targeted transdermal technology. We are committed to developing products with superior efficacy, reduced toxicities against approved medicines in hematological malignancies.

Targeted transdermal delivery

We are focused on creating meaningful benefits for patients with hematological malignancies. Each product we work on is reimagined and studied to develop new dose regimens and define optimal targets. Our approach establishes new indications and delivers superior outcomes.

Careers

We are building a team dedicated to delivering breakthrough, transformative outcomes for patients with hematological malignancies. Learn more about career opportunities at Starton.

News and Events

12/27/19

Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide

NEW YORK, Dec. 27, 2019 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion…

12/26/19

Starton Therapeutics: Announcing Name Change for ChemioCare Inc

DECEMBER 26 2019, NEW YORK – ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced it has changed the name of the…